Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. (Q34001564)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

review article

1 reference

title

Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Markus J Seibel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Dieter Felsenberg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

23 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

42-55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

Patients receiving intravenous bisphosphonates should avoid invasive dental procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Efficacy of risedronate on clinical vertebral fractures within six months.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised r

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Mineralisation defects after pamidronate for Paget's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Secondary Hyperparathyroidism Associated with Dichloromethane Diphosphonate Treatment of Paget's Disease*

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

The spectrum of bone disease in 200 chronic hemodialysis patients: a correlation between clinical, biochemical and histological findings

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

The acute-phase response after bisphosphonate administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Severe oral ulcerations induced by alendronate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Alendronate gastric ulcers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Pamidronate and uveitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonates and ocular inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Renal failure associated with intravenous diphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0688

1 reference

7 January 2021

Zoledronic Acid and renal toxicity: data from French adverse effect reporting database

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaws associated with cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Avascular necrosis of the jaws: risk factors in metastatic cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaw and bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the maxilla as a complication to chemotherapy: a case report.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaws: a complication of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

New developments in the pathogenesis and treatment of steroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Glucocorticoid therapy for myasthenia gravis resulting in resorption of the mandibular condyles

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Immunomodulatory drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Postradiation osteonecrosis of the mandible: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonates: new antiangiogenic molecules in cancer treatment?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonate-associated osteonecrosis of the jaw

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Bisphosphonates-related jaw osteonecrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Jaw avascular bone necrosis associated with long-term use of biphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

[Bisphosphonates and osteonecrosis of the jaw]

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis and bisphosphonates: correlation versus causation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Osteonecrosis of the jaw associated with pamidronate therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0688

7 January 2021

Identifiers

DOI

10.1038/NCPONC0688

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17183355%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference